Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi58-vi62; doi:10.1093/annonc/mdm226
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chiuri, V.
Right arrow Articles by Lorusso, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiuri, V.
Right arrow Articles by Lorusso, V
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

breast and ovarian cancer

Clinical and therapeutic perspectives of gene expression profiling for breast cancer

VE Chiuri1,*, G Leo2 and V Lorusso1

1 Oncologia Medica, Ospedale ‘V. Fazzi’, Lecce
2 Laboratorio di Biologia Molecolare, Ospedale ‘V. Fazzi’, Lecce, Italy

* Correspondence to: Dr V. E. Chiuri, Oncologia Medica, Ospedale ‘V. Fazzi’, p.zza F. Muratore, 73100 Lecce, Italy. Tel: +39-0832661808; Fax: +39-0832661965; E-mail: chiuriv{at}yahoo.it

The standard method for defining prognosis for patients with breast cancer is an integrated model including clinicopathological features, such as tumour size, histological grade, nodal involvement, hormone receptor status and HER-2 overexpression. Nowadays, two multigene prognostic models can stratify patients in new categories of risk. Notably, clinicopathological prognostic prediction and genomic signatures are discordant in at least 30% of cases. For this reason, two trials are going on, aiming to validate clinical utility of gene profiling.

As regards the predictive value of genomic assays, many models have been carried out, demonstrating the capacity to identify with high sensitivity and specificity resistant and non-resistant tumours, differently from the traditional markers. These predictors, however, need to be validated by prospective clinical trials.

Key words: breast cancer, gene expression profiling, predictive, prognostic


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.